AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC
Conditions: RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseas es; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue Interventions: Drug: Pralsetinib; Drug: Carboplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pembrolizumab; Drug: Gemcitabine Sponsor: Blueprint Medicines Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Alimta | Cancer | Cancer & Oncology | Carcinoma | Embryonal Carcinoma | Non-Small Cell Lung Cancer | Research | Study